AML | Bladder | CML | Colorectal | Endometrial | Glioma | NSCL | Pancreatic | Renal | SCL | Thyroid | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 years Survival [%] | 23.6 | 78.1 | 55.2 | 63.6 | 68.6 | 33.4 | 18 | 5.5 | 69.5 | 6.2 | 97.2 | |
Degree-Entropy | 2.16 | 1.52 | 2.11 | 1.63 | 1.6 | 2.22 | 2.23 | 2 | 1.59 | 2.06 | 1.38 | |
Cycle-Basis | 108 | 20 | 115 | 58 | 45 | 128 | 75 | 72 | 52 | 150 | 24 | |
Nominal Betti | 107 | 20 | 114 | 51 | 45 | 128 | 50 | 38 | 51 | 149 | 24 | |
Best Betti | 95 | 15 | 101 | 41 | 35 | 109 | 37 | 29 | 34 | 131 | 17 | |
Equivalent Targets | FLT3 | ITGA3 | ||||||||||
HRAS | MAPK3 | AKT1 | AKT3 | HRAS | ITGA6 | HRAS | ||||||
NRAS | MAPK1 | AKT2 | AKT2 | PDPK1 | NRAS | KRAS | KRAS | HIF1A | ITGA2B | NRAS | ||
KRAS | AKT3 | AKT1 | ILK | KRAS | EPAS1 | ITGB1 | KRAS | |||||
ITGA2 | ||||||||||||
ITGAV |